CYTARABINE, SULFASALAZINE, IDARUBICIN HYDROCHLORIDE
APHP211176
Phase 2 small_molecule active
Quick answer
CYTARABINE, SULFASALAZINE, IDARUBICIN HYDROCHLORIDE for Recently diagnosed non favorable Acute Myeloid Leukemias is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Recently diagnosed non favorable Acute Myeloid Leukemias
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active